Gilead Sciencesvs.Neurocrine Biosciences
GILD vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 13× larger than Neurocrine Biosciences by market cap; year to date, Gilead Sciences leads (+19.6% vs +1.2%).
Side by side
| GILD | NBIX | |
|---|---|---|
| Market cap | $180B | $14.3B |
| Price | $147.10 | $141.25 |
| Today | +0.2% | −1.5% |
| Return YTD | +19.6% | +1.2% |
| Return 1Y | +25.7% | +4.7% |
| Since June 26, 2026 | +15.0% | −16.2% |
| P/E | — | 20.3 |
| P/S | 5.9 | 4.3 |
| P/B | 15.2 | 3.9 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →More GILD & NBIX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and NBIX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →